Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
Scenic Biotech , a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.
- Scenic Biotech , a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.
- Under the terms of the agreement, Scenic Biotech will be entitled to an upfront payment and potential additional payments contingent upon achievement of a range of research, development and commercial milestones.
- “Working with a world leader in drug discovery and development is an important validation of our Cell-Seq platform’s unique capability to link cellular pathways to drug targets,” commented Oscar Izeboud, PhD, CEO of Scenic Biotech.
- Both collaborations leverage the Cell-Seq platform’s ability to provide genetic insights leading to the discovery and development of novel therapeutics.